1/11
10:32 am
imrx
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]
High
Report
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]
1/10
07:02 pm
imrx
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]
High
Report
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]
1/8
05:51 pm
imrx
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]
Low
Report
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]
1/7
04:00 pm
imrx
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
High
Report
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
12/30
03:52 pm
imrx
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]
Low
Report
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]
12/23
09:02 am
imrx
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 [Yahoo! Finance]
Medium
Report
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 [Yahoo! Finance]
12/23
08:00 am
imrx
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Medium
Report
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
12/20
01:30 am
imrx
Medium
Report
12/17
05:28 pm
imrx
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA [Yahoo! Finance]
Medium
Report
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA [Yahoo! Finance]
12/17
04:05 pm
imrx
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
Medium
Report
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
12/16
04:37 pm
imrx
Immuneering (NASDAQ:IMRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Immuneering (NASDAQ:IMRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
08:37 am
imrx
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
Low
Report
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
12/16
08:00 am
imrx
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Medium
Report
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
12/15
09:31 am
imrx
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO) [Yahoo! Finance]
Medium
Report
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO) [Yahoo! Finance]
12/12
10:47 am
imrx
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Medium
Report
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
11/25
09:08 am
imrx
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
imrx
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
11/15
01:42 am
imrx
11/13
09:01 am
imrx
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Medium
Report
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
11/12
09:14 pm
imrx
Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:05 pm
imrx
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
Low
Report
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
11/11
05:42 pm
imrx
Immuneering Q3 2025 Earnings Preview [Seeking Alpha]
Low
Report
Immuneering Q3 2025 Earnings Preview [Seeking Alpha]